Trueline Therapeutics Inc.: Trueline Therapeutics Announces Completion of IND-Enabling Studies for MCL1 Inhibitor TTX-810
- TTX-810 is designed for rapid clearance to circumvent mechanism-based risks of MCL1 inhibition - High potency affords robust anti-tumor effects whilst preserving cardiomyocyte viability - Trueline
Source: finanznachrichten.de